Feyza Bahar DOĞAN, Caner İŞEVİ, Mehmet Gökhan PİRZİRENLİ
Journal of Experimental and Clinical Medicine - 2026;43(1):110-112
Dasatinib, a BCR-ABL tyrosine kinase inhibitor widely used in the treatment of chronic myeloid leukemia (CML), is known to cause pleural effusion; however, chylothorax, especially in bilateral and recurrent forms, is extremely rare. We present the case of a 38-year-old male with CML who developed refractory bilateral chylothorax after six months of dasatinib therapy. Despite chest tube drainage and dietary intervention, the effusion persisted until the drug was discontinued. Following dasatinib cessation, pleural drainage gradually resolved, and no recurrence was observed. This case highlights the importance of recognizing dasatinib-induced chylothorax and the need for drug withdrawal in refractory presentations.
